By Ian Gilson, PhD,
CFA
NASDAQ:MBII
READ THE FULL MBII RESEARCH
REPORT
Zacks Small Cap. Research has initiated coverage on Marrone Bio
Innovations (MBII) with a $2.00 price
target.
Fourth quarter revenue was ahead of projections due to better than
expected sales of Venerate.
In Dec. 2018 Marrone launched TerraConnect, a new biological soil
applied and seed treatment platform delivering high performance
products with a broad range of tools to improve and protect crops.
TerraConnect is a tailored solution that unites biology and
chemistry to protect plants and improve yields.
Expanded international distribution network. Added Vietnam,
Cambodia, Turkey, South Korea.
Marrone Bio Innovations is the only pure play in the growing
biopesticide arena. The company has a large patent portfolio that
should generate new products and product extensions over at least
the next five years. The R&D is focused on the largest market
segments. The existing market of chemical pesticides is expected to
give way to more ecologically sound biopesticides especially within
the fruit and vegetables segment for both organic and conventional
growers.
SUBSCRIBE TO ZACKS SMALL CAP
RESEARCH to receive our articles and reports emailed
directly to you each morning. Please visit our website for additional information on Zacks
SCR.
DISCLOSURE: Zacks SCR has received compensation from the
issuer directly or from an investor relations consulting firm,
engaged by the issuer, for providing research coverage for a period
of no less than one year. Research articles, as seen here, are part
of the service Zacks provides and Zacks receives quarterly payments
totaling a maximum fee of $30,000 annually for these services. Full
Disclaimer HERE.